rs841 — GCH1

GCH1 and the BH4-Nitric Oxide Axis — When Endothelial Engines Run Lean

Nitric oxide (NO) is the blood vessel's primary vasodilator — the molecule that keeps arteries relaxed, blood flowing smoothly, and blood pressure in check. GCH1 (GTP Cyclohydrolase 1)¹¹ GCH1 (GTP Cyclohydrolase 1)
the rate-limiting enzyme in tetrahydrobiopterin synthesis is a gatekeeper of NO production. Without adequate BH4 — the essential cofactor that keeps endothelial nitric oxide synthase (eNOS) in its productive, coupled state — eNOS stops making NO and starts making superoxide instead. This switch, called NOS uncoupling²² NOS uncoupling
when eNOS produces reactive oxygen species rather than NO, worsening both oxidative stress and vascular tone, is a central driver of hypertensive vascular disease. The rs841 variant in GCH1 tags individuals whose BH4 synthesis capacity is genetically constrained.

The Mechanism

rs841 sits in an intron of GCH1 on chromosome 14 (and also in the 3' UTR of one transcript variant), on the minus strand of the genome. Papers describe it using coding-strand notation as "C+243T" — where the T allele (corresponding to A on the plus strand, the allele reported in genome files) is the functional variant. GCH1 forms part of a two-haplotype-block structure in the gene; rs841 anchors one of these blocks alongside rs10483639 and rs3783641, collectively tagging a haplotype associated with reduced GCH1 expression or activity³³ haplotype associated with reduced GCH1 expression or activity
Wolkow et al. 2014: the same haplotype block drives both oxidative stress markers and endothelial function measures.

When GCH1 activity is reduced, BH4 supply to eNOS falls. Coupled eNOS transfers electrons from NADPH to L-arginine and produces NO. Uncoupled eNOS — lacking BH4 — transfers those electrons to molecular oxygen, producing superoxide instead. The superoxide then reacts with remaining NO to form peroxynitrite, which in turn oxidizes GTPCH1 itself (releasing zinc and inhibiting BH4 synthesis further), creating a feed-forward cycle of vascular dysfunction⁴⁴ feed-forward cycle of vascular dysfunction
Wu et al. 2021: peroxynitrite → GTPCH1 inhibition → less BH4 → more uncoupling → more peroxynitrite.

The Evidence

The strongest direct evidence for rs841 comes from a study of 117 type 2 diabetes patients (Wolkow et al., PLoS One 2014)⁵⁵ study of 117 type 2 diabetes patients (Wolkow et al., PLoS One 2014)
five GCH1 polymorphisms assessed across two haplotype blocks against endothelial and oxidative stress markers. Among the five SNPs, rs841 showed association with flow-mediated dilation (a standard endothelial function test; p=0.01), malondialdehyde levels (a lipid peroxidation marker; p=0.0015), and von Willebrand factor (an endothelial injury marker; p=0.03). These associations held within the context of multiple GCH1 polymorphisms in the same analysis, supporting that rs841 carries independent information about BH4-NO pathway function.

Mechanistic evidence from mouse genetics is compelling: endothelial-specific GCH1 deletion virtually abolished NO bioactivity, elevated superoxide production, and raised blood pressure⁶⁶ virtually abolished NO bioactivity, elevated superoxide production, and raised blood pressure
Chuaiphichai et al. Hypertension 2014; ex vivo BH4 analogue sepiapterin restored normal endothelial function. A 2026 follow-up using inducible endothelial Gch1 deletion revealed sex-specific dynamics⁷⁷ sex-specific dynamics
Chuaiphichai et al. Hypertension 2026: males showed progressive hypertension over 24 weeks; females showed earlier but non-progressive hypertension that worsened dramatically during pregnancy.

In a Chinese Han case-control study of 558 ischemic stroke patients and 557 controls, rs841 showed independent association with stroke risk (dominant model p=0.00006); combined with rs1049255 (another GCH1 variant), the risk genotype carried an OR of 1.73 (95% CI 1.27–2.35)⁸⁸ OR of 1.73 (95% CI 1.27–2.35)
Yan et al. Acta Pharmacol Sin 2011.

A protective signal also emerged in obstructive sleep apnea research⁹⁹ obstructive sleep apnea research
Sheikhi Kouhsar et al. Sci Rep 2019: 94 OSA patients and 100 controls, where the heterozygous GA genotype inversely associated with OSA severity (p=0.005) — consistent with the heterozygous state preserving partial BH4 production and maintaining vascular tone during intermittent hypoxia.

Practical Actions

For AA homozygotes, the GCH1 BH4 pathway is most constrained. Targeted strategies include BH4 precursor support via sapropterin or sepiapterin (prescription) and nutritional cofactor optimization. Riboflavin (B2) is required for GCH1 enzyme activity; folate in its active 5-MTHF form contributes to BH4 recycling through the dihydrobiopterin reductase pathway. L-arginine (the NOS substrate) optimization matters less than BH4 availability, since uncoupled eNOS cannot productively use L-arginine regardless of its concentration. Nitrate-rich vegetables (beetroot, spinach, arugula) provide an eNOS-independent NO source that remains functional even when BH4 is depleted.

Sex context matters: women with A-allele variants should be aware that the BH4-NO pathway becomes particularly important during pregnancy, where endothelial function is critical for uteroplacental blood flow.

Interactions

rs841 is in partial linkage disequilibrium with rs10483639, rs3783641, and rs8007267 — all within the GCH1 two-haplotype-block structure. Combined haplotype analyses consistently show stronger associations than individual SNPs. The GCH1 pathway interacts with eNOS (NOS3; rs1799983) — GCH1 variants determine BH4 availability while NOS3 variants affect eNOS expression and activity; combined risk genotypes are expected to compound NOS uncoupling further.

GCH1 variants also interact with the folate-methylation cycle: 5-MTHF is required to maintain BH4 in its reduced (active) form via the tetrahydrobiopterin recycling pathway. MTHFR variants (rs1801133) that reduce methylfolate availability therefore compound the BH4 deficiency risk in GCH1 A-allele carriers.